Regeneron has signed a collaboration deal potentially worth $1 billion with RNAi experts Alnylam Pharmaceuticals, to develop and commercialise drugs targeting eye, central nervous system (CNS ...
News of a significant earnings beat propelled Regeneron Pharmaceuticals (NASDAQ: REGN) to a nearly 5% share price gain on the second trading day of the week. The company posted its fourth-quarter ...
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection ...
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician ...
Regeneron Pharmaceuticals, Inc. and CytomX Therapeutics, Inc. have announced a strategic research collaboration within the field of conditionally activated bispecific therapeutics for the ...
Facilities for Regeneron Canada in thriving Mississauga/GTA biotech hub signal its growth and readiness to bring more of its life-transforming innovative medicines for serious diseases to ...
LONG ISLAND, New York (WABC) -- Long Island is well represented this year at the prestigious Regeneron Science Talent Search. The annual search is the longest running of its kind, and seeks the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback